Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19


Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials.

Johansen KGV, Tarp S, Astrup A, Lund H, Pagsberg AK, Christensen R.

PLoS One. 2017 Aug 29;12(8):e0183821. doi: 10.1371/journal.pone.0183821. eCollection 2017. Review.


Role of the Dynorphin/Kappa Opioid Receptor System in the Motivational Effects of Ethanol.

Anderson RI, Becker HC.

Alcohol Clin Exp Res. 2017 Aug;41(8):1402-1418. doi: 10.1111/acer.13406. Epub 2017 Jun 5. Review.


Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity.

Cservenka A, Yardley MM, Ray LA.

Am J Addict. 2017 Aug;26(5):516-525. doi: 10.1111/ajad.12463. Epub 2016 Nov 4. Review.


Delta Opioid Pharmacology in Relation to Alcohol Behaviors.

Alongkronrusmee D, Chiang T, van Rijn RM.

Handb Exp Pharmacol. 2016 Jun 18. [Epub ahead of print]


Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood.

Calleja-Conde J, Echeverry-Alzate V, Giné E, Bühler KM, Nadal R, Maldonado R, Rodríguez de Fonseca F, Gual A, López-Moreno JA.

Br J Pharmacol. 2016 Aug;173(16):2490-505. doi: 10.1111/bph.13526. Epub 2016 Jul 18.


Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.

Jones JD, Luba RR, Vogelman JL, Comer SD.

Am J Addict. 2016 Jan;25(1):41-8. doi: 10.1111/ajad.12316. Epub 2015 Dec 21.


The pharmacogenetics of alcohol use disorder.

Jones JD, Comer SD, Kranzler HR.

Alcohol Clin Exp Res. 2015 Mar;39(3):391-402. doi: 10.1111/acer.12643. Epub 2015 Feb 19. Review.


Pharmacogenetics of OPRM1.

Crist RC, Berrettini WH.

Pharmacol Biochem Behav. 2014 Aug;123:25-33. doi: 10.1016/j.pbb.2013.10.018. Epub 2013 Nov 5. Review.


Targeted opioid receptor antagonists in the treatment of alcohol use disorders.

Niciu MJ, Arias AJ.

CNS Drugs. 2013 Oct;27(10):777-87. doi: 10.1007/s40263-013-0096-4. Review.


Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.

Sobczak M, Sałaga M, Storr MA, Fichna J.

J Gastroenterol. 2014 Jan;49(1):24-45. doi: 10.1007/s00535-013-0753-x. Epub 2013 Feb 9. Review.


The genetics of the opioid system and specific drug addictions.

Levran O, Yuferov V, Kreek MJ.

Hum Genet. 2012 Jun;131(6):823-42. doi: 10.1007/s00439-012-1172-4. Epub 2012 May 1. Review.


Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment.

Mroziewicz M, Tyndale RF.

Addict Sci Clin Pract. 2010 Dec;5(2):17-29. Review.


Beyond the ubiquitous relapse curve: a data-informed approach.

Zywiak WH, Kenna GA, Westerberg VS.

Front Psychiatry. 2011 Mar 30;2:12. doi: 10.3389/fpsyt.2011.00012. eCollection 2011.


Neuroscience of behavioral and pharmacological treatments for addictions.

Potenza MN, Sofuoglu M, Carroll KM, Rounsaville BJ.

Neuron. 2011 Feb 24;69(4):695-712. doi: 10.1016/j.neuron.2011.02.009. Review.


Medication treatment of different types of alcoholism.

Johnson BA.

Am J Psychiatry. 2010 Jun;167(6):630-9. doi: 10.1176/appi.ajp.2010.08101500. Review.


Pharmacogenetics of alcohol and alcohol dependence treatment.

Kranzler HR, Edenberg HJ.

Curr Pharm Des. 2010;16(19):2141-8. Review.


A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys.

Vallender EJ, Rüedi-Bettschen D, Miller GM, Platt DM.

Drug Alcohol Depend. 2010 Jun 1;109(1-3):252-6. doi: 10.1016/j.drugalcdep.2010.01.005. Epub 2010 Feb 13.


OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Mague SD, Blendy JA.

Drug Alcohol Depend. 2010 May 1;108(3):172-82. doi: 10.1016/j.drugalcdep.2009.12.016. Epub 2010 Jan 13. Review.

Supplemental Content

Support Center